Novo Nordisk testing its blockbuster GLP-1 drugs in Alzheimer’s

Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s…